Heat Biologics Story

Requested story not found. it has been either deleted or moved. View all stories for Heat Biologics.

Heat Biologics Latest Timeline

Heat Biologics is listed for 0.00. The company has price-to-book (P/B) ratio of 0.48. Some equities with similar Price to Book (P/B) outperform the market in the long run. Heat Biologics recorded a loss per share of 1.15. The entity had not issued any dividends in recent years. The firm had 1-7 split on the 11th of December 2020.

Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. Note that the Heat Biologics information on this page should be used as a complementary analysis to other Heat Biologics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.

If you are still planning to invest in Heat Biologics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Heat Biologics' history and understand the potential risks before investing.